New live tumor test could predict immunotherapy success

NCT ID NCT05520099

Ongoing Knowledge-focused Sponsor: Elephas Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Jun 17, 2026 · Updated 22 times

Summary

This study collects fresh tumor samples from 416 people with various cancers to develop a live diagnostic platform. The goal is to train the platform to predict whether a patient will respond to immunotherapy, using standard imaging as the reference. Participants provide tissue and health data, but no experimental treatment is given.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

AdventHealth Orlando

Orlando, Florida, 32803, United States
CARTI Cancer Center

Little Rock, Arkansas, 72205, United States
Cleveland Clinic Florida

Stuart, Florida, 34994, United States
John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Memorial Health System

Pembroke Pines, Florida, 33026, United States
Meritus Center for Clinical Research

Hagerstown, Maryland, 21742, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
Salinas Valley Memorial Healthcare System

Salinas, California, 93901, United States
University of Louisville James Graham Brown Cancer Center

Louisville, Kentucky, 40202, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
University of South Florida (Tampa General Hospital)

Tampa, Florida, 33606, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma cancer clear cell renal carcinoma colorectal cancer colorectal neoplasm cutaneous melanoma endometrial cancer endometrium neoplasm head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma hepatocellular carcinoma kidney cancer liver cancer Liver Neoplasms lung cancer lung neoplasm Lynch syndrome melanoma neoplasm non-small cell lung carcinoma nonpapillary renal cell carcinoma renal cell carcinoma skin cancer skin neoplasm Squamous Cell Carcinoma of Head and Neck urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER CANCER CLEAR CELL RENAL CELL CANCER (CCRCC) COLORECTAL CANCER CUTANEOUS MELANOMA DMMR COLORECTAL CANCER ENDOMETRIAL CANCER ENDOMETRIAL CANCER HEAD AND NECK CANCER (H&N) HEPATOCELLULAR CARCINOMA (HCC) IMMUNOTHERAPY KIDNEY CANCER LIVER CANCER LUNG CANCER (NSCLC) MSI-H COLORECTAL CANCER NSCLC (NON-SMALL CELL LUNG CANCER) SKIN CANCER SOLID TUMOR CANCER SQUAMOUS CELL CARCINOMA HEAD AND NECK CANCER (HNSCC) UROTHELIAL CARCINOMA BLADDER